Effects of guanadrel on patients with thyrotoxicosis

S. Rubenfeld, B. M. Patten, Peter Kohler

Research output: Contribution to journalArticle

Abstract

Eleven patients with Graves' disease were treated with guanadrel sulfate and observed for changes in neuromuscular and cardiovascular manifestations. No notable changes in pulse rate or muscle strength were detected in either these patients during a three-day pretreatment period or in five control patients with Graves' disease receiving placebo for six days. Thyroid hormone levels were not altered by seven days of guanadrel sulfate therapy (5 to 20 mg orally every six hours), and no adverse side effects were encountered. Mean supine resting pulse fell from 102 ± 6 (mean ± SEM) to 90 ± 3 beats per minute (P <.02). The patient's proximal and distal muscle strengths were initially decreased, when compared with healthy subjects, and improved substantially with guanadrel therapy. We conclude that guanadrel sulfate may be useful in the symptomatic management of patients with thyrotoxicosis.

Original languageEnglish (US)
Pages (from-to)1106-1108
Number of pages3
JournalArchives of Internal Medicine
Volume138
Issue number7
DOIs
StatePublished - 1978
Externally publishedYes

Fingerprint

Thyrotoxicosis
Graves Disease
Muscle Strength
Neuromuscular Manifestations
Thyroid Hormones
Healthy Volunteers
Heart Rate
Placebos
guanadrel
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effects of guanadrel on patients with thyrotoxicosis. / Rubenfeld, S.; Patten, B. M.; Kohler, Peter.

In: Archives of Internal Medicine, Vol. 138, No. 7, 1978, p. 1106-1108.

Research output: Contribution to journalArticle

Rubenfeld, S. ; Patten, B. M. ; Kohler, Peter. / Effects of guanadrel on patients with thyrotoxicosis. In: Archives of Internal Medicine. 1978 ; Vol. 138, No. 7. pp. 1106-1108.
@article{c315521775ba4d02865b3ec772d95fdc,
title = "Effects of guanadrel on patients with thyrotoxicosis",
abstract = "Eleven patients with Graves' disease were treated with guanadrel sulfate and observed for changes in neuromuscular and cardiovascular manifestations. No notable changes in pulse rate or muscle strength were detected in either these patients during a three-day pretreatment period or in five control patients with Graves' disease receiving placebo for six days. Thyroid hormone levels were not altered by seven days of guanadrel sulfate therapy (5 to 20 mg orally every six hours), and no adverse side effects were encountered. Mean supine resting pulse fell from 102 ± 6 (mean ± SEM) to 90 ± 3 beats per minute (P <.02). The patient's proximal and distal muscle strengths were initially decreased, when compared with healthy subjects, and improved substantially with guanadrel therapy. We conclude that guanadrel sulfate may be useful in the symptomatic management of patients with thyrotoxicosis.",
author = "S. Rubenfeld and Patten, {B. M.} and Peter Kohler",
year = "1978",
doi = "10.1001/archinte.138.7.1106",
language = "English (US)",
volume = "138",
pages = "1106--1108",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Effects of guanadrel on patients with thyrotoxicosis

AU - Rubenfeld, S.

AU - Patten, B. M.

AU - Kohler, Peter

PY - 1978

Y1 - 1978

N2 - Eleven patients with Graves' disease were treated with guanadrel sulfate and observed for changes in neuromuscular and cardiovascular manifestations. No notable changes in pulse rate or muscle strength were detected in either these patients during a three-day pretreatment period or in five control patients with Graves' disease receiving placebo for six days. Thyroid hormone levels were not altered by seven days of guanadrel sulfate therapy (5 to 20 mg orally every six hours), and no adverse side effects were encountered. Mean supine resting pulse fell from 102 ± 6 (mean ± SEM) to 90 ± 3 beats per minute (P <.02). The patient's proximal and distal muscle strengths were initially decreased, when compared with healthy subjects, and improved substantially with guanadrel therapy. We conclude that guanadrel sulfate may be useful in the symptomatic management of patients with thyrotoxicosis.

AB - Eleven patients with Graves' disease were treated with guanadrel sulfate and observed for changes in neuromuscular and cardiovascular manifestations. No notable changes in pulse rate or muscle strength were detected in either these patients during a three-day pretreatment period or in five control patients with Graves' disease receiving placebo for six days. Thyroid hormone levels were not altered by seven days of guanadrel sulfate therapy (5 to 20 mg orally every six hours), and no adverse side effects were encountered. Mean supine resting pulse fell from 102 ± 6 (mean ± SEM) to 90 ± 3 beats per minute (P <.02). The patient's proximal and distal muscle strengths were initially decreased, when compared with healthy subjects, and improved substantially with guanadrel therapy. We conclude that guanadrel sulfate may be useful in the symptomatic management of patients with thyrotoxicosis.

UR - http://www.scopus.com/inward/record.url?scp=0018209285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018209285&partnerID=8YFLogxK

U2 - 10.1001/archinte.138.7.1106

DO - 10.1001/archinte.138.7.1106

M3 - Article

VL - 138

SP - 1106

EP - 1108

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 7

ER -